QuidelOrtho Corp
QDEL$2.18B
Mid CapNASDAQIn Vitro & In Vivo Diagnostic Substances🇺🇸North AmericaSAN DIEGO7.1K employees
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
QDEL News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
No drugs found in this phase.
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply